1. Guidelines and Good Clinical Practice Recommendations for Contrast
Enhanced Ultrasound (CEUS) in the Liver – Update 2020
The present, updated document describes the fourth iteration of recommendations for the hepatic use of contrast enhanced ultrasound (CEUS), first initiated in 2004 by the European Federation of Societies for Ultrasound in Medicine and
Biology (EFSUMB). The previous updated editions of the
guidelines reflected changes in the available contrast agents
and updated the guidelines not only for hepatic but also for
non-hepatic applications.
The 2012 guideline requires updating as previously the differences of the contrast agents were not precisely described and
the differences in contrast phases as well as handling were not
clearly indicated. In addition, more evidence has been published for all contrast agents. The update also reflects the
most recent developments in contrast agents, including the
United States Food and Drug Administration (FDA) approval
as well as the extensive Asian experience, to produce a truly
international perspective.
These guidelines and recommendations provide general
advice on the use of ultrasound contrast agents (UCA) and
are intended to create standard protocols for the use and administration of UCA in liver applications on an international
basis to improve the management of patients.
2.The EFSUMB Guidelines and Recommendations for the Clinical
Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic
Applications: Update 2017 (Short Version)
The updated version of the EFSUMB guidelines on the application of non-hepatic contrast-enhanced ultrasound (CEUS)
deals with the use of microbubble ultrasound contrast outside
the liver in the many established and emerging applications.
4. Formularz świadomej zgody pacjenta na badanie CEUS